ReShape Lifesciences Inc. Files 8-K for Material Agreement
Ticker: HIND · Form: 8-K · Filed: Jun 12, 2025 · CIK: 1427570
| Field | Detail |
|---|---|
| Company | Reshape Lifesciences Inc. (HIND) |
| Form Type | 8-K |
| Filed Date | Jun 12, 2025 |
| Risk Level | medium |
| Sentiment | neutral |
Sentiment: neutral
Topics: material-agreement, 8-k, filing
Related Tickers: RSLS
TL;DR
RESHAPE LIFESCIENCES (RSLS) signed a material definitive agreement on June 8, 2025. 8-K filed.
AI Summary
On June 8, 2025, ReShape Lifesciences Inc. entered into a material definitive agreement. The filing also includes Regulation FD disclosures and financial statements with exhibits. The company is incorporated in Delaware and its principal executive offices are located at 18 Technology Drive, Suite 110, Irvine, CA.
Why It Matters
This 8-K filing indicates a significant new agreement for ReShape Lifesciences Inc., which could impact its business operations and financial future.
Risk Assessment
Risk Level: medium — Material definitive agreements can introduce new risks or opportunities, requiring further analysis of the agreement's terms.
Key Players & Entities
- ReShape Lifesciences Inc. (company) — Registrant
- June 8, 2025 (date) — Date of earliest event reported
- Delaware (jurisdiction) — State of incorporation
- 18 Technology Drive, Suite 110, Irvine, CA 92618 (address) — Address of principal executive offices
- Obalon Therapeutics Inc (company) — Former company name
FAQ
What is the nature of the material definitive agreement entered into by ReShape Lifesciences Inc. on June 8, 2025?
The filing states that ReShape Lifesciences Inc. entered into a material definitive agreement on June 8, 2025, but the specific details of this agreement are not provided in the provided text.
What other items are included in this 8-K filing?
This 8-K filing also includes Regulation FD Disclosure and Financial Statements and Exhibits.
When was ReShape Lifesciences Inc. incorporated and where are its principal executive offices located?
ReShape Lifesciences Inc. was incorporated in Delaware and its principal executive offices are located at 18 Technology Drive, Suite 110, Irvine, CA 92618.
What was the former name of ReShape Lifesciences Inc.?
The former name of ReShape Lifesciences Inc. was Obalon Therapeutics Inc.
What is the SEC file number and film number for this filing?
The SEC file number is 001-37897 and the film number is 251042795.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on June 12, 2025 regarding ReShape Lifesciences Inc. (HIND).